Clinical Trials - September 25, 2019
Immunicum announces data analysis from Phase II trial
The company has announced the complete analysis of the data from the Phase II MERECA clinical trial. The study evaluated the therapeutic impact of the company’s lead candidate, ilixadencel, in combination with Sutent (sunitinib) in metastatic Renal Cell Carcinoma (RCC) patients. The data on survival benefit in all patients showed that a higher percentage of […]
Clinical Trials - August 29, 2019
Exciting results from Immunicum
The company has announced positive Phase II MERECA results, including complete tumor responses in metastatic renal cell carcinoma patients. The study’s objective was to evaluate the therapeutic impact of combining ilixadencel with Sutent (sunitinib). The most important outcome was achieving five complete responses, defined as eradication of the cancerous tumor and no further evidence of […]
Clinical Trials - June 12, 2019
Immunicum announces positive trial results
The company has completed and announces positive results from the its Phase I/II clinical trial examining the safety and tolerability of the lead candidate, ilixadencel, in combination with tyrosine kinase inhibitors (TKIs) in six patients with Gastrointestinal Stromal Tumors (GIST), a rare and difficult-to-treat disease indication. The trial showed that ilixadencel had a favorable safety […]
Clinical Trials - February 11, 2019
First patient treated in Immunicum trial
The first patient has been treated in the Phase Ib/II ILIAD clinical trial evaluating the safety and efficacy of Immunicum’s lead product in development, ilixadencel, in combination with checkpoint inhibitors (CPIs) in three cancer indications: head and neck cancer, non-small cell lung cancer and gastric cancer. The ILIAD trial is an open-label multicenter study fully sponsored […]
Clinical Trials - February 16, 2017
Immunicum’s clinical trial application approved
Immunicum announces that the Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) in France has approved the company’s Clinical Trial Application (CTA) for INTUVAX. The CTA approval enables Immunicum to include patients in France in its ongoing Phase II study – MERECA (MEtastatic REnal Cell CArcinoma) – for the treatment of […]
Financing - June 23, 2016
Immunicum raises approx SEK 128 million in oversubscribed rights issue
Immunicum’s rights issue of approximately SEK 111 million, which ended on June 14, 2016, was oversubscribed. In view of the strong demand from both new and existing shareholders the over-allotment option has been exercises in part, amounting to approximately SEK 17 million. Immunicum’s proceeds of the issue thereby totaled approximately SEK 128 million before transaction costs. Immunicum’s extra general meeting, […]
